Search AI Products and News

Quantum artificial intelligence startup SandboxAQ announced the successful completion of its Series E funding round, raising $450 million. This round attracted investment from industry giants including Google, Nvidia, and BNP Paribas, bringing SandboxAQ's total funding to $950 million. The company stated that the funds will be used to accelerate the development of its large quantum models and foster collaborations across various industries. Image note: Image generated by AI, image licensing provider Midjourney.

Insilico Medicine, a biopharmaceutical company focused on generative artificial intelligence, today announced the successful completion of a $110 million Series E financing round. The round was led by a private equity fund under Value Partners Group (HKG:0806), Pudong New Area Investment, Shanghai Pudong Development Bank Group, Xicheng Capital, and Yixing Guokong. Several new investors focused on the industry and technology sectors also participated, alongside continued support from existing investors.

Insilico Medicine recently announced the closing of a $110 million Series E financing round, led by Value Partners, a Hong Kong-based firm, with participation from existing and new investors. The funds will be used to refine the company's AI models and support pivotal clinical trials for its lead candidate drug in idiopathic pulmonary fibrosis. The company's small molecule inhibitor, ISM001-055, was recently officially named rentosertib by the U.S. Adopted Names Council, marking a significant milestone for this AI-generated drug candidate.